TKI anti HER1/EGFR and HER2/neu for COVID-19: living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	breast cancer - HER2-positive	breast cancer - HR positive

	la/mBC - HER2 positive - 2nd Line (L2)	la/mBC - HR-positive - 1st line (L1)
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus capecitabine	WJOG6110B/ELTOP
lapatinib plus fulvestrant		CALGB 40302
lapatinib plus letrozole		EGF30008 ... EGF30008 ...
lapatinib plus trastuzumab	EGF104900

Study type: